Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.

Iivanainen S, Koivunen JP.

Int J Mol Sci. 2020 Jan 15;21(2). pii: E556. doi: 10.3390/ijms21020556. Review.

2.

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.

Iivanainen S, Ahvonen J, Knuuttila A, Tiainen S, Koivunen JP.

ESMO Open. 2019 Aug 16;4(4):e000531. doi: 10.1136/esmoopen-2019-000531. eCollection 2019.

3.

Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer.

Honkanen TJ, Tikkanen A, Karihtala P, Mäkinen M, Väyrynen JP, Koivunen JP.

Sci Rep. 2019 Jul 29;9(1):10961. doi: 10.1038/s41598-019-47375-2.

4.

An unbiased in vitro screen for activating epidermal growth factor receptor mutations.

Chakroborty D, Kurppa KJ, Paatero I, Ojala VK, Koivu M, Tamirat MZ, Koivunen JP, Jänne PA, Johnson MS, Elo LL, Elenius K.

J Biol Chem. 2019 Jun 14;294(24):9377-9389. doi: 10.1074/jbc.RA118.006336. Epub 2019 Apr 5.

5.

Association of diagnostic delays to survival in lung cancer: single center experience.

Alanen V, Koivunen JP.

Acta Oncol. 2019 Jul;58(7):1056-1061. doi: 10.1080/0284186X.2019.1590635. Epub 2019 Apr 2.

PMID:
30938249
6.

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study.

Iivanainen S, Alanko T, Peltola K, Konkola T, Ekström J, Virtanen H, Koivunen JP.

J Cancer Res Clin Oncol. 2019 Mar;145(3):765-774. doi: 10.1007/s00432-018-02835-6. Epub 2019 Jan 21.

7.

Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients.

Iivanainen S, Koivunen JP.

Oncology. 2019;96(3):125-131. doi: 10.1159/000493193. Epub 2018 Oct 31.

PMID:
30380551
8.

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.

Moilanen T, Jokimäki A, Tenhunen O, Koivunen JP.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1613-1621. doi: 10.1007/s00432-018-2682-9. Epub 2018 Jun 5.

PMID:
29872916
9.

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab.

Honkanen TJ, Moilanen T, Karihtala P, Tiainen S, Auvinen P, Väyrynen JP, Mäkinen M, Koivunen JP.

Sci Rep. 2017 Dec 21;7(1):18027. doi: 10.1038/s41598-017-18266-1.

10.

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer.

Moilanen T, Mustanoja S, Karihtala P, Koivunen JP.

ESMO Open. 2017 Jul 16;2(3):e000202. doi: 10.1136/esmoopen-2017-000202. eCollection 2017.

11.

HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.

Honkanen T, Wilenius E, Koivunen P, Koivunen JP.

Int J Oncol. 2017 Aug;51(2):599-606. doi: 10.3892/ijo.2017.4048. Epub 2017 Jun 21.

PMID:
28656214
12.

MEK and PI3K inhibition in solid tumors: rationale and evidence to date.

Jokinen E, Koivunen JP.

Ther Adv Med Oncol. 2015 May;7(3):170-80. doi: 10.1177/1758834015571111. Review.

13.

Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.

Jokinen E, Koivunen JP.

Int J Oncol. 2015 Sep;47(3):1103-10. doi: 10.3892/ijo.2015.3071. Epub 2015 Jul 2.

PMID:
26135106
14.

EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models.

Laurila N, Koivunen JP.

Med Oncol. 2015 Jul;32(7):205. doi: 10.1007/s12032-015-0627-6. Epub 2015 Jun 17.

PMID:
26081015
15.

Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features.

Jokinen E, Laurila N, Koivunen P, Koivunen JP.

Oncotarget. 2014 Oct 15;5(19):9295-307.

16.

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy.

Jokinen E, Laurila N, Koivunen JP.

BMC Cancer. 2012 Dec 21;12:612. doi: 10.1186/1471-2407-12-612.

17.

A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance.

Taube E, Jokinen E, Koivunen P, Koivunen JP.

Int J Cancer. 2012 Aug 15;131(4):970-9. doi: 10.1002/ijc.26461. Epub 2011 Nov 8.

18.

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.

Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA.

Br J Cancer. 2008 Jul 22;99(2):245-52. doi: 10.1038/sj.bjc.6604469. Epub 2008 Jul 1.

19.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA.

Clin Cancer Res. 2008 Jul 1;14(13):4275-83. doi: 10.1158/1078-0432.CCR-08-0168.

Supplemental Content

Loading ...
Support Center